OASMIA PHARMACE/ADR (OASM) Upgraded to “Buy” at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of OASMIA PHARMACE/ADR (NASDAQ:OASM) from a hold rating to a buy rating in a research report report published on Friday morning, ValuEngine reports.

OASMIA PHARMACE/ADR stock opened at $1.84 on Friday. OASMIA PHARMACE/ADR has a 12 month low of $1.20 and a 12 month high of $5.70.

OASMIA PHARMACE/ADR (NASDAQ:OASM) last released its earnings results on Friday, March 1st. The company reported ($0.04) EPS for the quarter. OASMIA PHARMACE/ADR had a negative return on equity of 42.16% and a negative net margin of 6,025.94%. The company had revenue of $0.16 million during the quarter.

A hedge fund recently bought a new stake in OASMIA PHARMACE/ADR stock. Deutsche Bank AG bought a new position in OASMIA PHARMACE/ADR (NASDAQ:OASM) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,800 shares of the company’s stock, valued at approximately $29,000. 0.25% of the stock is owned by institutional investors.

About OASMIA PHARMACE/ADR

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company's approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs.

See Also: Trading based on a resistance level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OASMIA PHARMACE/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OASMIA PHARMACE/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Atara Biotherapeutics  Now Covered by Stifel Nicolaus
Atara Biotherapeutics Now Covered by Stifel Nicolaus
Critical Contrast: MFC Bancorp  and Bancolombia
Critical Contrast: MFC Bancorp and Bancolombia
Paragon Banking Group’s  Hold Rating Reiterated at Numis Securities
Paragon Banking Group’s Hold Rating Reiterated at Numis Securities
Short Interest in Moleculin Biotech Inc  Grows By 327.4%
Short Interest in Moleculin Biotech Inc Grows By 327.4%
OrganiGram  Sets New 52-Week High at $11.30
OrganiGram Sets New 52-Week High at $11.30
Weekly Analysts’ Ratings Changes for Seres Therapeutics
Weekly Analysts’ Ratings Changes for Seres Therapeutics


© 2006-2019 Ticker Report